Patient demographics and baseline characteristics at entry into IFM 2010-02
| Characteristic . | n = 50 . |
|---|---|
| ISS stage at diagnosis, n (%) | |
| II/III | 20 (59) |
| Lytic bone lesions, n (%) | |
| Yes | 34 (87) |
| Number of lytic lesions: 3-6 | 3 (7.7) |
| Number of lytic lesions: >6 | 16 (41) |
| Osseous fracture | 8 (20.5) |
| Medullary compression | 1 (2.6) |
| Plasmacytoma | 6 (12) |
| Median β2-microglobulin, mg/L (range) | 3.2 (1-13) |
| 3.5-5.5 mg/L, n (%) | 16 (44) |
| >5.5 mg/L, n (%) | 19 (53) |
| Median albumin, g/L (range) | 39 (25-48) |
| Median serum creatinine, µmol/L (range) | 76.5 (53-138) |
| >115 µmol/L, n (%) | 1 (2) |
| Median hemoglobin, g/dL (range) | 11.1 (8.6-15) |
| <10 g/dL, n (%) | 14 (28) |
| Median neutrophils, ×109/L (range) | 2.9 (.6-13) |
| <1000 g/L, n (%) | 2 (4) |
| Median platelets, ×109/L (range) | 180 (65-458) |
| <100 g/L, n (%) | 6 (12) |
| Circulating plasma cells (yes, %) | 3 (6) |
| Adverse FISH cytogenetics | |
| At study entry, n (%) | 50/50 |
| del(17p), n (%) | 22 (46)* |
| t(4;14), n (%) | 32 (64)* |
| At diagnosis, n (%) | 45/50 |
| del(17p), n (%) | 14 (39) |
| t(4;14), n (%) | 26 (70) |
| Characteristic . | n = 50 . |
|---|---|
| ISS stage at diagnosis, n (%) | |
| II/III | 20 (59) |
| Lytic bone lesions, n (%) | |
| Yes | 34 (87) |
| Number of lytic lesions: 3-6 | 3 (7.7) |
| Number of lytic lesions: >6 | 16 (41) |
| Osseous fracture | 8 (20.5) |
| Medullary compression | 1 (2.6) |
| Plasmacytoma | 6 (12) |
| Median β2-microglobulin, mg/L (range) | 3.2 (1-13) |
| 3.5-5.5 mg/L, n (%) | 16 (44) |
| >5.5 mg/L, n (%) | 19 (53) |
| Median albumin, g/L (range) | 39 (25-48) |
| Median serum creatinine, µmol/L (range) | 76.5 (53-138) |
| >115 µmol/L, n (%) | 1 (2) |
| Median hemoglobin, g/dL (range) | 11.1 (8.6-15) |
| <10 g/dL, n (%) | 14 (28) |
| Median neutrophils, ×109/L (range) | 2.9 (.6-13) |
| <1000 g/L, n (%) | 2 (4) |
| Median platelets, ×109/L (range) | 180 (65-458) |
| <100 g/L, n (%) | 6 (12) |
| Circulating plasma cells (yes, %) | 3 (6) |
| Adverse FISH cytogenetics | |
| At study entry, n (%) | 50/50 |
| del(17p), n (%) | 22 (46)* |
| t(4;14), n (%) | 32 (64)* |
| At diagnosis, n (%) | 45/50 |
| del(17p), n (%) | 14 (39) |
| t(4;14), n (%) | 26 (70) |
High-risk cytogenetics by FISH consisted of deletion 17p or t(4;14) at diagnosis and/or at entry in IFM 2010-02 trial. Patients considered not measurable based on serum intact Ig and urine light-chain excretion, were measurable if they had serum immunoglobulin free light chain (FLC) more than 100 mg/L and an abnormal FLC ratio.
Two patients were both del(17p) and t(4;14).